anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The active control will be Sulphadoxine-Pyrimethamine (SP), the current standard of care for malaria chemoprevention for SCA in Uganda and Malawi. This will also be provided by Guilin Pharmaceutical Co. Ltd as their generic World Health Organization-approved sulphadoxine-pyrimethamine 500/25mg tablets. It will be administered as monthly single-day courses of SP at approximate doses of S=25mg/kg and P=1.25mg/kg.
OBJECTIVE: This study aimed to evaluate the effect of orthognathic surgery on masseter volume in patients with skeletal Class III malocclusion with facial asymmetry and the effect of masseter volume on stability in orthognathic surgery.
METHODS: This research studied 16 patients with Class III malocclusion with facial asymmetry who received combined orthodontic-orthognathic treatment and underwent craniofacial computed tomography (CT) before (T0), 2 weeks after (T1), and 6 months after (T2) surgery. Three-dimensional (3D) CT images were retrospectively analyzed, using 3D volume reconstruction to obtain the masseter volume and examine the impact of the masseter volume on stability in orthognathic surgery.
RESULTS: A statistically significant difference ( P < 0.05) in the volume of the masseter was found up to 6 months after orthognathic surgery compared with the preoperative period, and the reduction in the masticatory muscle volume on the lengthened side is greater than on the shortened side ( P < 0.05). The volume of both masseters differed according to facial asymmetry, and the difference was significantly reduced after orthognathic surgery ( P < 0.05). During the period time (T1-T2), cephalometric maxillary marker points were not significantly different ( P > 0.05), and mandibular marker points were significantly anteriorly shifted ( P < 0.05). There was an association between the masseter volume and anterior shift of point B (R > 0.5, P < 0.05), the upward and anterior shifts of the gonion point differed between the lengthened and shortened sides ( P < 0.05).
CONCLUSION: The size of the masseter becomes smaller 6 months after orthognathic surgery, and orthognathic surgery improves both bone and soft tissue symmetry. A larger sagittal relapse of mandibular setback occurred in patients with greater masseter volume. Considering these alterations may be helpful in planning orthognathic surgery.
This invention is directed to conducting chemical reactions in reverse micelle or microemulsion systems comprising a substantially discontinuous phase including a polar fluid, typically an aqueous fluid, and a microemulsion promoter, typically a surfactant, for facilitating the formation of reverse micelles in the system.  The system further includes a substantially continuous phase including a non-polar or low-polarity fluid material which is a gas under standard temperature and pressure and has a critical density, and which is generally a water-insoluble fluid in a near critical or supercritical state.  Thus, the microemulsion system is maintained at a pressure and temperature such that the density of the non-polar or low-polarity fluid exceeds the critical density thereof.  The method of carrying out chemical reactions generally comprises forming a first reverse micelle system including an aqueous fluid including reverse micelles in a water-insoluble fluid in the supercritical state.  Then, a first reactant is introduced into the first reverse micelle system, and a chemical reaction is carried out with the first reactant to form a reaction product.  In general, the first reactant can be incorporated into, and the product formed in, the reverse micelles.  A second reactant can also be incorporated in the first reverse micelle system which is capable of reacting with the first reactant to form a product.
In recent years, machine learning, particularly Natural Language Processing, has emerged as a valuable tool for analyzing unstructured health data, such as headache anamneses. Studies demonstrate that algorithms can identify specific patterns and automate headache diagnoses. Various studies have also shown that machine learning algorithms achieve high diagnostic accuracy in distinguishing between headache types, including migraine and cluster headaches. Additionally, machine learning models are being used to predict potential triggers, treatment responses, and even the progression of headache disorders. Digital headache diaries and trigger-analysis apps are becoming increasingly important in therapy. Through digital health applications, new scalable non-drug options for headache and migraine therapy are available.
This is the study protocol for a multi-centre interventional open-label randomized controlled feasibility trial to evaluate the feasibility of delivering informational support via an online learning platform to Malaysian parents of children with leukemia or lymphoma. The study will be conducted in two pediatric oncology centres in Kuala Lumpur, Malaysia. Study participants will include adult parents of children who were diagnosed with leukemia or lymphoma in the preceding 3. Block randomization will be used to allocate participants into the intervention or a waitlist-control arm. The intervention group will receive access to e-Hematological Oncology Parent Education (eHOPE), which provides information support for parents in the local Malay language, via an online learning platform. They will also receive usual care, which includes verbal explanations and caregiver education in the course of their child's treatment process. Parents will be able to access multimedia information designed to support them in the care of their sick child, and will need to complete 4 self-paced activities over a period of 8 weeks. The waitlist-control group will receive usual care, and at the end of 8 weeks, will also receive access to eHOPE. The primary outcome of this trial will be the change in caregiving knowledge, whereas secondary outcomes include caregiving self-efficacy and coping self-efficacy. Descriptive data on feasibility will include duration of recruitment to achieve targeted sample size, the drop-out rate of participants and identified barriers to implementation.
Hepatocellular carcinoma (HCC) is a type of primary cancer of the liver that is being diagnosed in the U.S. population with increasing frequency. While surgery is the first line of treatment, many patients are not eligible for surgical removal. Current non-surgical treatments for HCC are not fully effective and can have substantial side-effects. This study utilizes a type of radiation treatment called proton beam that can deliver high doses of radiotherapy to tumors within the liver while minimizing damage to surrounding healthy tissues. The treatment is non-invasive and is given on an out-patient basis over a three week coarse. The study will evaluate the effectiveness and side-effects of this therapy by tracking patient's outcomes following treatment.
Group 1 (n=12): ustekinumab 45 mg (or 90 mg for patients \> 100 kg) subcutaneously at baseline (W0), 4 weeks later (W4), and every 12 weeks until week 24 (i.e. W0, W4, and W16).
Treatment for pulmonary metastatic disease may include surgery, chemotherapy, radiation therapy, or a combination of treatments. However, several variables may exclude participants from these treatments such as multiple tumors, multiple previous surgeries, pulmonary dysfunction, or co-morbid medical conditions. For these participants, percutaneous cryoablation may be a suitable option.

Ablation of metastatic lung tumors is a rapidly expanding area within interventional oncology. Cryotherapy, radiofrequency, laser, and microwave have all been shown to be effective. Cryotherapy offers a wide range of anatomic and tumor treatment options because of the ability to visualize the ice under imaging guidance and the preservation of collagenous tissue structure. Cryoablation has been extensively performed in the prostate and kidney with favorable outcomes reported in the literature. More recently, cryoablation has been shown to be safe in the treatment of lung tumors with CT guidance.
The invention discloses a method for preventing and treating sow metritis. For a pig with metritis, the appetite is poor or lost, the body temperature is raised, the nose tray is dry, the pig frequently shows straining, and a large amount of yellow-white or brown smelly secretions flow out of the vagina and are frequently mixed with embryonic membrane debris. If the pig is not treated in time, sepsis or pyemia is often formed. The uterine mucous membrane can become thicken gradually due to chronic stimulation of inflammation, and the secretions periodically flow out of the vagina of a sick pig. Although the pig is estrous periodically, the pig is infertile after multiple times of mating. Chronic metritis is often accompanied by systemic symptoms. A hog house should be kept clean and dry, and clean bedding has to be replaced when a sow is parturient. During delivery assistance, strict attention should be paid to sterilization, and operations are required to be light and meticulous. After delivery, breeding management should be enhanced, and artificial fecundation should strictly follow a sterilization system. After taking all fetuses and embryonic membranes in dystocia, an antibiotic is filled into a capsule, and then the capsule with the antibiotic is directly slipped into the uterine cavity to prevent the metritis.
In medication switching period, treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation 24 mg, and the dose of the other antipsychotics will be gradually reduced, finally switching to monotherapy with 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) by Week 4. In treatment period, 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) will be orally administered for 52 weeks.
Heart failure is a health problem worldwide. There are some drugs for it, including digoxin, spironolactone, captopril, and valsartan, but some of these drugs can produce secondary effects, such as arrhythmia, cough, hyperkalemia, hyponatremia and hypotension. The aim of this research was to evaluate the biological activity of coumarin (2H-chromen-2-one) and its derivatives (3BrAcet-C, 3-4Br-Ph-C, 4-CN-7D-C, 4-Me-7-Ph-C and 6Br-3-D-C) against ischemia/reperfusion injury as a therapeutic alternative for heart failure. In addition, the biological activity of the coumarin derivative 4-Me-7-Ph-C on left ventricular pressure (LVP) was determined in the absence or presence of ouabain and nifedipine at a dose of 1 nM using an isolated rat heart model. The results showed that i) the coumarin derivative 4-Me-7-Ph-C significantly decreased the infarct area (p+=+0.05) compared with 3BrAcet-C, 3-4Br-Ph-C, 4-CN-7D-C, and 6Br-3-D-C; and ii) 4-Me-7-Ph-C increased LVP in a dose-dependent manner, which effect was inhibited by nifedipine. These data suggest that coumarin 4-Me-7-Ph-C may act as a type-L calcium channel activator, so it could be a good agent to treat heart failure.
BACKGROUND: Despite advancements in antibiotic therapy and resuscitation protocols, sepsis and septic shock remain major contributors to morbidity and mortality in children. We aimed to investigate the utility of soluble urokinase plasminogen activator receptor (suPAR) for the early detection of septic shock and to evaluate its accuracy in predicting mortality.
METHODS: A prospective study was conducted in a tertiary pediatric emergency department (ED), enrolling patients diagnosed with the sepsis, severe sepsis, or septic shock. In addition to assessing infection biomarkers such as C-reactive protein and procalcitonin, suPAR levels were quantified upon admission using enzyme-linked immunosorbent assay. The primary outcome measure was 30-day mortality.
RESULTS: Overall 72 patients and 80 healthy children included. Plasma suPAR levels demonstrated a statistically significant elevation in the sepsis, severe sepsis, and septic shock groups compared with the control group (p < 0.001 for all). The septic shock group exhibited the highest suPAR levels upon admission, surpassing both the sepsis and severe sepsis groups (p = 0.009 and 0.042). ROC analysis underscored the promising potential of suPAR with an AUC of 0.832 for septic shock. Analysis of mortality prediction revealed significantly higher suPAR levels in nonsurvivors than survivors (9.7 ng/mL vs. 4.2 ng/mL; p < 0.001). Employing plasma suPAR levels to discriminate between mortality and survival, a threshold of ≥7.0 ng/mL demonstrated a sensitivity of 90.9% and specificity of 71.0%.
CONCLUSION: Plasma suPAR levels have the potential as a biomarker for predicting mortality in children with septic shock. In pediatric septic shock, the presence of plasma suPAR ≥7 ng/mL along with an underlying disease significantly increases the risk of mortality.
Risk Summary

LIVMARLI has low absorption following oral administration, and breastfeeding is not expected to result in exposure of the infant to LIVMARLI at the recommended dose [see Clinical Pharmacology (12.3)]. There are no data on the presence of LIVMARLI in human milk, the effects on the breastfed infant, or the effects on milk production. Patients with ALGS or PFIC can have FSV deficiency as part of their disease. Maralixibat may reduce absorption of fat-soluble vitamins [see Warnings and Precautions (5.3)]. Monitor FSV levels and supplement FSV intake, if FSV deficiency is observed during lactation. The developmental and health benefits of breastfeeding should be considered along with the mother's need for LIVMARLI and any potential adverse effects on the breastfed child from LIVMARLI or from the underlying maternal condition.
The invention relates to the technical field of genetic engineering antibodies, in particular to a bispecific antibody targeting TROP2 and CD3, and a preparation method and application thereof. Wherein the anti-human TROP2 antibody comprises a heavy chain variable region having the amino acid sequence shown in SEQ ID No.2 and a light chain variable region; the light chain variable region has the amino acid sequence shown in SEQ ID NO. 1. The anti-human CD3 antibody has the amino acid sequences shown as SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO. 6. The invention provides a bispecific antibody with good binding to human TROP2 antigen and binding to human CD3, which provides a basis for the development of immunotherapeutic drugs with TROP2 as a target.
PROBLEM TO BE SOLVED: To provide regenerative therapies comprising implanting in a subject cell delivery matrix localizing fat-derived endothelial cells.SOLUTION: Cell delivery matrices and methods for facilitating local delivery of fat-derived endothelial cells to a target tissue, body cavity, or joint are described. The cell delivery matrix may be a three-dimensional matrix scaffold comprising fibrin derived from the patient's own body. The cell delivery matrix may be biocompatible and semi-permeable. The cell delivery matrix used in the methods may be comprised of any degradable, bioabsorbable or non-degradable, biocompatible polymer. Regenerative therapies comprising implanting in the subject cell delivery matrices localizing the fat-derived endothelial cells are described. The cell delivery matrices maintain the fat-derived endothelial cells at the target for a therapeutically effective amount of time. The fat- derived endothelial cells can be allogenic or syngeneic to the subject. The endothelial cells may be delivered alone or in combination with other therapeutic agents.
INTRODUCTION: Previous studies have suggested that hypertensive disorders of pregnancy increase risk of hypospadias, but so far none have focused on the influence of maternal chronic hypertension (CH). This study aimed to conduct a systematic review and meta-analysis of currently available observational data to assess the association of maternal CH with hypospadias risk.
METHODS: Literature searches were performed using EMBASE, SCOPUS, Pubmed, and manual methods according to PRISMA 2020 guidelines and MOOSE checklist. Eligible articles were included in the study and assessed for quality using the Newcastle-Ottawa Scale (NOS). Extracted data were presented in review tables. Pooled analysis for unadjusted and adjusted effect sizes was used to determine OR and 95%CI using DerSimonian and Laird model. Heterogeneity was tested using I2 test, and publication bias was examined using funnel plots. Sensitivity analyses are done to address uncertainties.
RESULTS: Searches yielded a total of 1130 publications with six eligible studies and high NOS quality score (6-9) were selected as depicted in extended summary figure. There were 519 hypospadias patients with maternal CH among those six eligible studies for analysis. After sensitivity analysis, there is one study that is excluded due to different hypospadias definition. Among the 5 remaining studies, it is found that there is an elevated risk of hypospadias in the context of maternal CH as determined by pooled unadjusted and adjusted OR (OR 1.50 95%CI 1.17-1.93; aOR 1.77 95%CI 1.54-2.04 respectively). Heterogeneity was high in unadjusted pooled analysis (I2 = 73% P = 0.005) and low in adjusted analysis (I2 = 0% P = 0.40)). Funnel plots were symmetrical in both analyses indicating a lack of publication bias.
CONCLUSIONS: This meta-analysis indicates that maternal CH increases risk of hypospadias in male offspring. Future studies should weigh in biological mechanisms and pharmacological effects to elaborate the pathogenesis of this association.
Lichen planus (LP) is an idiopathic inflammatory dermatosis of the skin and mucous membranes. Cutaneous lesions present as pink polygonal papules on the flexor wrists, trunk, thighs, shin and the dorsal hands. Oral lichen planus (OLP) represents a unique subset of LP and is often the sole manifestation of this disease. Clinically, the lesions can be reticulate, erythematous, atrophic or erosive, with the erosive form being the most common. Lesions can be found anywhere in the oral mucosa and are associated with burning pain which is worsened while eating. The risk of development of squamous cell carcinoma has been estimated to be as high as 5%. Treatments for oral lichen planus involve high potency topical steroid, systemic steroids, oral/topical retinoids and immunosuppressants. However, the long term side effects of steroids (e.g. striae, skin atrophy, telangiectasias, tachyphylaxis, secondary candidiasis and perioral dermatitis) prevent more extensive utilization except in the most severe cases. Given the debilitating nature of OLP, risk of malignant transformation, and long term side effects associated with current therapies, a safe intervention is needed for this disorder.

Tacrolimus and pimecrolimus may have fewer side affects than topical steroids. Recently, in an open label trial of 19 patients with recalcitrant erosive lichen planus, tacrolimus decreased the area of ulceration by 73% after an eight week course. Local irritation was the most common side effect. However, tacrolimus comes in an ointment base, a poorly tolerated vehicle for oral lesions. Topical treatment of oral lesions has also been compromised by problems with maintaining sufficient contact time between poorly adherent cream and ointment preparations and moist mucous membrane surfaces.

This study is designed to evaluate the topical application of pimecrolimus 1% cream when applied twice daily with occlusion in the treatment of oral lichen planus.
FIELD: chemico-pharmaceutical industry. SUBSTANCE: described is stable pharmaceutical solid composition comprising sodium analapryl. Method comprises mixing sodium analapryl maleate with carrier, sodium alkali compound and water. Moistened compound is then dried and is subsequently converted into tablets. When water is added to process as described above, acid-alkali reaction occurs wherein analapryl maleate is converted into more stable sodium analapryl salt. Invention allows for stability of tablets that do not decompose and makes it possible to prepare tablets having good hardness. EFFECT: more efficient preparation method. 19 cl, 3 ex
L-Lactate is required as a fuel for the continuous firing of nociceptors that produce many of the manifestations of chronic pain. Polymer D-lactic acid (PDLA) forms a spontaneous non-enzymatic, thermodynamically favored stereocomplex with sequestration of l-lactate or “trapping” of l-lactate. Injection or topical application of PDLA can reduce pain by decreasing the l-lactate available to activated nociceptors without sequestering lactate in non-disrupted nerves. C fibers and unmyelinated visceral afferents are most sensitive to the analgesia produced by PDLA. PDLA can be used to ameliorate pain from a wide variety of medical conditions including skin ulcers, wounds and burns; causalgia, radiculopathy, neuropathy; arthritis; and cancer. PDLA oligomers can be inexpensively produced from d-lactic acid in a home microwave. The predicted toxicity of PDLA is low and topical application or injection into perineural tissues for relief of pain may be very safe.
NEW MATERIAL:A compound shown by formula I (R<1> and R<2> are, H, lower alkyl or R<1> and R<2> together with N are bonded to form 5- or 6-membered group which may contain O with the proviso a case that both R<1> and R<2> are H is omitted). EXAMPLE:2-(3,4-Dimethoxycinnamoylamino)-N-methylbenzoic acid amide. USE:Useful as a remedy for allergic diseases and also as a synthetic intermediate thereof. PREPARATION:A reactive derivative (e.g. acid chloride or acid bromide) shown by formula II at the carboxyl group is reacted with a compound shown by formula III to give a compound shown by formula I. The compound shown by formula I is obtained extremely readily and in high yield even at room temperature.
Pediatric and adult participants initiated IV treatment with sebelipase alfa at a dose of 1 mg/kg qow. Participants were considered for a dose adjustment at the discretion of the Investigator and in consultation with the Sponsor. Dose escalation to 3 mg/kg qow was considered if pre-defined dose-escalation criteria were met. If these criteria continued to be met, a subsequent dose escalation to 3 mg/kg every week (qw) was considered. Dose decreases as low as 0.35 mg/kg qow were permitted based upon evidence of intolerance to sebelipase alfa treatment. Participants who completed the 96-week treatment period were permitted to continue receiving sebelipase alfa in an expanded treatment period for up to 48 weeks, pending local drug availability and study participation status.
PURPOSE:To obtain the titled novel plasminogen activator useful as a fibriolytic agent, having improved affinity for fibrin and high thrombus dissolving ability, by cultivating a cell strain derived from human and collecting and purifying the activator from the culture solution. CONSTITUTION:A cell strain (e.g., cell derived from human striated muscle sarcoma) derived from human is cultivated and a culture solution is collected and purified to give a novel plasminogen activator from human tissue having the following physical and chemical properties. Molecular weight: 62,000-73,000. Action and substrate specificity: converting inactive precursor plasminogen into plasmin and dissolving fibrin. Having higher affinity for fibrin than urokinase on the market. Km of synthetic substrate S-2288 is 3.6X10<-4>M, Vmax116mol/min.I.U. Optimum pH: 7-11. Stable pH: 4.5-11. Action suitable temperature: 30-45 deg.C. Temperature resistance: not deactivating under heating for 90min up to 50 deg.C. Isoelectric point: pH7.5-8.0.
A pulsatile pharmaceutical form consists of an apolar carrier contg. the pharmaceutical and a polar carrier contg. at least a fraction of the pharmaceutical. The dielectric constants of the 2 carriers is different by a factor of at least 2. The apolar carrier pref. has a dielectric constant of 20-0 (esp. 5-0) and is a hydrocarbon or a glycol or glycerol ester with an alkanoic or alkenoic acid.